Background: Nirmatrelvir/ritonavir (NMV/r) and three-day course remdesivir (3RDV) have
been approved as early treatments for COVID-19 outpatients not requiring supplemental …

Introduction Different antivirals are available for the treatment of outpatients with COVID-19.
Our aim was to describe a real-world experience of outpatient management of COVID-19 …

Summary Background Remdesivir (Veklury, Gilead Sciences, Foster City, CA, USA) and
nirmatrelvir–ritonavir (Paxlovid, Pfizer, New York, NY, USA) were reported to improve the …

Background Treatment of coronavirus disease 2019 (COVID-19) with nirmatrelvir plus
ritonavir (NMV-r) in high-risk nonhospitalized unvaccinated patients reduced the risk of …

This network meta-analysis compared the clinical efficacy and safety of anti-viral agents for
the prevention of disease progression among non-hospitalized patients with COVID-19 …

Background The efficacy of nirmatrelvir plus ritonavir (NMV-r) for vaccinated COVID-19
patients at high risk of progression is not adequately recognised. To address this gap, we …

Background Nirmatrelvir is an orally administered severe acute respiratory syndrome
coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in …

Background In immunocompromised patients, persistent SARS-CoV-2 viral shedding and
relapsing COVID-19 pneumonia have been described. Currently, little is known about the …

Nirmatrelvir‐ritonavir (NR) was approved to treat SARS‐CoV‐2 positive outpatients at high
risk of progression to severe disease, based on a randomized trial in unvaccinated patients …

Background: Randomized trial evidence suggests that some antiviral drugs are effective in
patients with COVID-19. However, the comparative effectiveness of antiviral drugs in …